Huakang Biomedical Holdings Company Limited
Hong Kong Stock ExchangeTotal Valuation
Huakang Biomedical Holdings Company Limited carries a market capitalization of 102.58M, placing it among publicly traded companies globally. Its enterprise value stands at 12.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 102.58M |
| Enterprise Value | 12.57M |
Share Statistics
Huakang Biomedical Holdings Company Limited currently has 418.47M shares outstanding.
| Shares Outstanding | 418.47M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.64, and the price-to-book ratio stands at -7.59.
| PE Ratio | N/A |
| PS Ratio | 1.64 |
| PB Ratio | -7.59 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 0.51 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 237.26 |
Financial Position
Huakang Biomedical Holdings Company Limited maintains a current ratio of 4.08, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.07, indicating elevated leverage, while an interest coverage ratio of -127.00 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.08 |
| Quick Ratio | 2.51 |
| Debt / Equity | 10.07 |
| Debt / EBITDA | -0.76 |
| Interest Coverage | -127.00 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -8.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.62 |
Stock Price Statistics
Huakang Biomedical Holdings Company Limited's stock has declined approximately -46.21622% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.37.
| Beta (5Y) | N/A |
| 52-Week Price Change | -46.21622% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.37 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Huakang Biomedical Holdings Company Limited generated 24.63M in revenue and converted that into -5.78M in net income, yielding earnings per share of -0.01. EBITDA reached -6.73M, while operating income came in at -6.73M.
| Revenue | 24.63M |
| Gross Profit | 16.09M |
| Operating Income | -6.73M |
| Pretax Income | -5.78M |
| Net Income | -5.78M |
| EBITDA | -6.73M |
| EBIT | -6.73M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Huakang Biomedical Holdings Company Limited holds 32.94M in cash and equivalents against 5.14M in total debt, resulting in a net debt position of -30.09M. Total book value stands at -5.32M, with working capital of 40.34M providing operational flexibility.
| Cash & Cash Equivalents | 32.94M |
| Total Debt | 5.14M |
| Net Debt | -30.09M |
| Equity (Book Value) | -5.32M |
| Book Value Per Share | -0.01 |
| Working Capital | 40.34M |
Margins
Huakang Biomedical Holdings Company Limited operates with a gross margin of 65.34, reflecting its pricing power and cost economics. The operating margin of -27.33 and net profit margin of -23.48 provide insight into operational efficiency.
| Gross Margin | 65.34 |
| Operating Margin | -27.33 |
| Pretax Margin | -23.48 |
| Profit Margin | -23.48 |
| EBITDA Margin | -27.33 |
Scores
Huakang Biomedical Holdings Company Limited posts an Altman Z-Score of 2.30, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.30 |